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Glioblastoma (GBM) is the most common and devastating primary brain tumor. The presence of cancer stem cells (CSCs) has been
linked to their therapy resistance. Molecular and cellular components of the tumor microenvironment also play a fundamental role
in the aggressiveness of these tumors. In particular, high levels of hypoxia and reactive oxygen species participate in several aspects
of GBM biology. Moreover, GBM contains a large number of macrophages, which normally behave as immunosuppressive tumor-
supportive cells. In fact, the presence of both, hypoxia and M2-like macrophages, correlates with malignancy and poor prognosis in
gliomas. Antioxidant agents, as nutritional supplements, might have antitumor activity. Ocoxin® oral solution (OOS), in particular,
has anti-inflammatory and antioxidant properties, as well as antitumor properties in several neoplasia, without known side effects.
Here, we describe how OOS affects stem cell properties in certain GBMs, slowing down their tumor growth. In parallel, OOS has a
direct effect on macrophage polarization in vitro and in vivo, inhibiting the protumoral features of M2 macrophages. Therefore,
OOS could be a feasible candidate to be used in combination therapies during GBM treatment because it can target the highly
resilient CSCs as well as their supportive immune microenvironment, without adding toxicity to conventional treatments.
1. Introduction
Glioblastomas (GBMs) are the most aggressive form of pri-
mary brain tumors. Histologically, they are characterized by
pronounced hypercellularity, aberrant vasculature, and
necrotic regions [1]. Standard treatment of GBM consists of
maximal safe surgical resection followed by focal, fractionated
radiotherapy, in combination with concurrent and adjuvant
chemotherapy with the DNA alkylating agent temozolomide
(TMZ) [2]. In any case, the prognosis is still grim, with less
than 10% of GBM patients surviving 5 years after diagnosis,
so novel treatment modalities are urgently required.
GBM cancer stem cells (CSCs) are able to self-renew, dif-
ferentiate and repopulate the whole bulk of the tumor, and
they have been associated with tumor relapse after treatment
[3]. Maintenance of an undifferentiated state of GBM CSCs
seems to be controlled by cues from their niches, mainly vas-
cularized areas and hypoxic regions [4, 5]. Paradoxically,
hypoxia is associated with an increase in reactive oxygen spe-
cies (ROS) [6]. In fact, molecules that induce a decrease in
endogenous ROS levels have been recently associated with
the inhibition of CSC-like properties in GBM [7, 8].
Dietary supplements (including antioxidants) are widely
used among patients with cancer, with the potential to be
anticancer and antitoxic agents, reducing side effects.
Whereas some authors have reported undesirable interac-
tions with conventional therapies, others have suggested
a synergistic effect [9, 10]. Ocoxin® oral solution (OOS)
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is a nutritional supplement with recognized antioxidant,
anti-inflammatory and immunomodulatory properties.
The solution is composed, among others, of green tea
extract, glyzyrrhicic acid, and vitamins C, B6 and B12,
which have undergone a molecular activation process that
boosts their antioxidant and biological activities. It was
synthesized by combining two products, Viusid® and
Ocoxin®. The Viusid component has shown beneficial
effects in patients suffering from chronic hepatitis C and
cirrhosis, showing antioxidant and immunomodulatory
effects [11, 12]. OOS has also been tested in several cancer
clinical trials, resulting in a significant improvement in the
quality of life of patients, better tolerance to conventional
therapies, and an increase in the survival index [13]
(NCT01392131). Moreover, OOS antitumor effects have
been validated in vitro and in vivo in preclinical breast cancer
[14] and acute myeloid leukemia models [15], playing an
inhibitory role for the liver metastasis of colorectal carci-
noma [16, 17]. In all cases, when administered to animal
models, OOS showed no detrimental effects. In fact, it even
improved the overall health state of the mice.
Here, we have tested the effect of OOS in GBM models.
For that we have used primary cell lines, derived from patient
samples. We have observed that OOS has a dual function, it
reduces tumor growth in some GBM through the modulation
of CSC properties, and it shows a striking capacity to inhibit
M2-like macrophage polarization, both in vitro and in the
tumor environment. Moreover, pretreatment with OOS
reduces the protumoral function of M2 macrophages. There-
fore, OOS could be a good candidate to be used in combina-
tion therapies during GBM treatment, especially if we
consider that it has been marketed for years without any
report of adverse effects.
2. Materials and Methods
2.1. GBM Cell Culture. GBM1 (L0627) was provided by
Rosella Galli (San Raffaele Scientific Institute, Milan, Italy);
GBM2 (12O15) and GBM3 (12O01) were obtained by disso-
ciation of human GBM surgical specimens from patients
treated at Hospital Universitario 12 de Octubre (Madrid,
Spain). We obtained an informed consent for study partic-
ipation from both patients. None of them was under the
age of 18. The study was performed with the approval
and following the guidelines of the Research Ethics Com-
mittee of Hospital 12 de Octubre (CEI 14/023). Primary
GBM cells were cultured in Neurobasal medium (Invitro-
gen) supplemented with B27 (1 : 50, Invitrogen), Glutamax
(1 : 100, Invitrogen), penicillin-streptomycin (1 : 100, Lonza),
0.4% heparin (Sigma-Aldrich), 40 ng/ml EGF (PeproTech),
and 20ng/ml bFGF2 (PeproTech) and passaged after enzy-
matic disaggregation using Accumax (Millipore), as previ-
ously described [18].
2.2. GBM In Vitro Assays. For viability assays, 5000 cells were
seeded in triplicate wells of a 96-multiwell plate coated with
Matrigel (Becton-Dickinson, 15mg/ml stock solution diluted
1 : 100 in DMEM medium (Lonza)). 24 h later, cells were
treated with OOS (1 : 100) (Catalysis S.L.) and viability was
measured after 72 h of treatment. For that, cells were incu-
bated with Hoechst 33342 (1 : 200, Sigma-Aldrich) and pro-
pidium iodide (1 : 1000, Merck) and fluorescence was
measured in a Cytell Cell Imaging System (GE Healthcare
Life Sciences). Wells containing nontreated cells were con-
sidered as 100% viability for each tested cell line. For self-
renewal assays, GBM neurospheres were disaggregated into
single cells and plated in fresh medium in the absence of
OOS at a clonal density of 2.5 cells/μl in triplicate wells of a
96-multiwell plate. 24 hours later, GBM cell lines were
treated with OOS (1 : 100). The percentage of self-renewing
cells was determined 6 days after treatment by counting the
number of individual neurospheres that originated from
plated cells. Nontreated cells were used as a control.
2.3. Macrophage Isolation and Culture. Peritoneal macro-
phages were isolated as described in [19]. In brief, for macro-
phage isolation, 2.5ml of 3% thioglycollate (Sigma-Aldrich)
was injected into the peritoneum of C57BL/6 mice. Four days
later, peritoneal cells were harvested and 15000 cells/well
were seeded in a 96-multiwell plate for viability and ROS
assays. Otherwise, 2 5 × 106 cells/well were seeded in a 6-
multiwell plate for RNA isolation. Cells were cultured in
RPMI 1640 (Fisher Scientific) with 10% of heat-inactivated
fetal bovine serum (FBS, Fisher Scientific) and penicillin-
streptomycin (1 : 100, Lonza) for 3 h. The amount of FBS
was then reduced to 2% for overnight cell starvation. After
overnight starvation, cells were treated with or without
1 : 100 OOS, in the presence of the differentiation inducers:
LPS (200 ng/ml, InvivoGen), IL4 (20 ng/ml, PeproTech) or
GBM1 conditioned medium (CM, 1 : 1) (obtained after 72 h
incubation of GBM1 cells in neurosphere media). Control
cells were maintained in 2% FBS medium. After 24 h, LPS
and IL4 were removed but OOS was maintained for another
24 h before macrophage analysis.
2.4. Macrophage In Vitro Assays. Macrophage viability was
assessed using AlamarBlue reagent (Fisher Scientific). The
reagent was added to the media (1 : 10) and incubated for
4 h at 37°C and 5% CO2, protected from light. Fluorescence
of the samples was measured (excitation at 560nm and emis-
sion at 600 nm) in an Infinite 200 PRO microplate reader
(Tecan). Wells containing only culture media were used as
a background control for all the samples measured, and wells
containing nontreated cells were considered as 100% viabil-
ity. ROS measurement was performed using dihydroethi-
dium (DHE) reagent (Cayman Chemical). DHE was added
to the media (1 : 800) and incubated for 1 h at 37°C and 5%
CO2, protected from light. Fluorescence of the samples was
measured in a Cytell Cell Imaging System. Wells containing
only culture media were used as a background control for all
the samples measured, and wells containing nontreated cells
were considered as 100% ROS. For the coculture experiment,
2 5 × 106 macrophages were seeded per 6-multiwell plate.
After the overnight starvation, cells were treated with or
without 1 : 100 OOS, in the presence of IL4 (20 ng/ml,
PeproTech). Control macrophages were maintained in 2%
FBS medium. After 24 h, IL4 was removed but OOS was
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maintained for another 24h. After OOS removal, macro-
phages were washed and freshly dissociated GBM1 cells
(expressing the luciferase reporter) (250000 cells) were
added on top of the macrophages (in GBM media without
growth factors). Three days later, luciferin was added (150
μg/ml) and luminiscence was measured in an IVIS equip-
ment (Perkin Elmer).
2.5. Mouse Xenograft Assays. Animal care and experimental
procedures were performed in accordance with the European
Union and National Guidelines for the use of animals in
research and were reviewed and approved by the Research
Ethics and Animal Welfare Committee at our institution
(Instituto de Salud Carlos III, Madrid) (PROEX 244/14).
Heterotopic and orthotopic xenografts were performed as
previously described [20]. For heterotopic xenografts, 1 ×
106 cells were resuspended in culture media with Matrigel
(1 : 10, BD) and then subcutaneously injected into athymic
nude Foxn1numice (Harlan Iberica). When the subcutaneous
tumors were noticeable (around 4mm in diameter), OOS or
water was orally administered to the mice (100 μl/day, 5 day-
s/week). During the treatments, tumors were measured with
a caliper twice a week until mice sacrifice. Tumor volume was
calculated as 1/2 (length×width2). Relative tumor growth
was calculated in relation to tumor volume at day 1 of treat-
ment. For orthotopic xenografts, stereotactically guided
intracranial injections in athymic nude Foxn1nu mice were
performed by administering 0 5 × 105 GBM1 cells resus-
pended in 2 μl of culture media. The injections were made
into the striatum (coordinates: A-P, –0.5mm; M-L, +2mm;
and D-V, –3mm; related to the bregma) using a Hamilton
syringe. Mice were orally treated with OOS or water (200
μl/day, 5 days/week) 3 weeks after the intracranial injections
until mice were sacrificed at the onset of symptoms.
2.6. Tumor Tissue Analysis. At the endpoint, subcutaneous
tumors or brain tumors were dissected and the tissue was
fresh frozen for molecular analysis, dissociated for flow
cytometry analysis or fixed o/n in 4% paraformaldehyde
(Merck) and embedded in paraffin. Paraffin-embedded tissue
was cut with a microtome (Leica Microsystems) (3 μm sec-
tions), and sections were stained with hematoxylin-eosin
(H&E) or incubated with specific antibodies for immunohis-
tochemical- (IHC-) DAB staining.
2.7. Western Blot (WB). For immunoblot analysis, cells were
collected and rinsed in cold PBS. Samples were resuspended
in 0.1% SDS-RIPA buffer supplemented with a protease
inhibitor cocktail (Roche), incubated 20 minutes on ice and
centrifuged at 14000 rpm for 15min at 4°C. Protein con-
centration was determined using a commercially available
colorimetric assay (Pierce BCA Protein Assay Kit, Thermo
Scientific). Approximately 20 μg of protein were resolved
by 12% SDS-PAGE and transferred onto a nitrocellulose
membrane. Membranes were blocked for 1 h at room tem-
perature in 5% BSA in TBS-T (10mM Tris-HCl, pH 7.5,
100mM NaCl and 0.1% Tween-20) and then incubated o/n
at 4°C with the corresponding primary antibody diluted in
5% BSA in TBS-T. After washing 3 times with TBS-T, mem-
branes were incubated for 1 hour at room temperature with
their corresponding secondary antibody diluted in TBS-T.
Detection was done by enhanced chemiluminescence with
ECL (Millipore). Primary and secondary antibodies are
shown in Supp. Table S1 and S2, respectively.
2.8. Quantitative Real-Time PCR (qRT-PCR). RNA was
extracted from both frozen pellets of cells or frozen tissue sec-
tions with the High Pure RNA Isolation Kit (Roche) follow-
ing the manufacturer’s instructions. Total RNA (1 μg) was
reverse transcribed with the PrimeScript RT Reagent Kit
(TAKARA) in a total volume of 20μl. The product of this
retrotranscription was tenfold diluted for quantitative PCR
analysis. Quantitative real-time PCR (qRT-PCR) was per-
formed using the Light Cycler 480 (Roche) with SYBR
Premix Ex Taq (TAKARA) in LightCycler® 480 Multiwell
Plates using 10 μM of forward and reverse primers and
2μl of cDNA template (tenfold diluted). Cycling condi-
tions included an initial denaturation for 10 minutes at
95°C, followed by 45 cycles of 10 s at 95°C, 10 s at primer
hybridization temperature and 10 s at 72°C. Quantification of
gene expression was performed by the delta-delta Ct method,
and Ct values were calculated following the manufacturer’s
instructions (LightCycler Software, Roche). The expression
of the housekeeping genes Actin or RPII was used as an inter-
nal expression control. Primers used are indicated in Supp.
Table S3.
2.9. Flow Cytometry Analysis. Tumor cells were disaggregated
into individual cells with Accumax (5min, RT) and erythro-
cytes were lysed with Quicklysis (15min, RT; Cytognos)
before staining. Cells were stained with anti-CD44-FITC
(ImmunoTools, Supplementary Table S1) diluted in PBS
+0.5% BSA+2mM EDTA (staining buffer) for 20min on
ice and treated with PI (5 μg/ml, Sigma-Aldrich) for 5min
on ice. After staining, cells were washed with staining buffer
and analyzed by flow cytometry (FACSCalibur, Becton
Dickinson) using the FlowJo software.
2.10. Immunohistochemical Analysis (IHC). Tumors were
fixed o/n at 4°C in 4% paraformaldehyde (PFA, Merck),
rinsed with 0.1M phosphate buffer (PB), and dehydrated
by an ethanol gradient before embedding in paraffin for
microtome sectioning. Tumors were cut with a microtome
(Leica Microsystems), and paraffin sections (3 μm) were
dewaxed and rehydrated. Antigen retrieval was achieved by
microwaving the sections in 10mM sodium citrate (pH 6.0)
and endogenous peroxidase was blocked with 0.3% hydrogen
peroxide. Tissue sections were blocked with 5% BSA+10%
FBS in PB-Triton X-100 (0.1%) and incubated o/n at 4°C
with anti-Activated Caspase 3 in blocking buffer. Sections
were incubated with a secondary antibody labelled with bio-
tin (2 hours at room temperature) before incubation with
ABC-Peroxidase Solution (Thermo Scientific) for 30min at
room temperature. The peroxidase activity was developed
with DAB (Vector) and sections were counterstained with
hematoxylin. Images were acquired with a Leica DM4B
microscope and analyzed by using ImageJ software. The
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primary and secondary antibodies used are indicated in
Supp. Table S1 and S2, respectively.
2.11. Statistical Analysis. The survival of nude mice was
analyzed by the Kaplan-Meier method and evaluated with
a two-sided log-rank test. Student’s t-test was performed for
statistical analysis of in vitro studies. Data in graphs are pre-
sented as means± SEM. ∗P ≤ 0 05; ∗∗P ≤ 0 01; ∗∗∗P ≤ 0 001.
Statistical values of P > 0 05 were not considered significant.
3. Results
3.1. OOS Inhibits the Self-Renewal Capacity of Some GBM
CSCs. To explore the antitumor activity of OOS we used
three different primary GBM cell lines derived from human
samples, grown in the absence of serum and in the presence
of growth factors, in the form of floating neurospheres
enriched in CSCs [21]. Three days’ incubation in the pres-
ence of OOS (1 : 100) did not produce a significant change
in cell viability (Figure 1(a)). However, the same concentra-
tion of OOS inhibited the capacity of GBM1 and GBM2 cells
to grow at highly diluted conditions (self-renewal assay)
(Figure 1(b)), which is a feature related to CSCs and tumor-
initiating properties [22]. Interestingly, we did not observe
a significant effect of OOS on the self-renewal capacity of
GBM3 cells. In agreement with these results, we observed a
significant inhibition of CSC-related markers in GBM1 cells
treated with OOS for 24h (Figure 1(c)), whereas the supple-
ment did not change the expression of these genes in GBM3
cells (Figure 1(d)).
GBM is a very heterogeneous group of tumors. In fact, we
know that the behavior of GBM1 and GBM2 differs from
GBM3 as the first two grow in a highly angiogenic manner
in the mouse’s brain, whereas the third one generates very
invasive tumors (Gargini et al., manuscript in preparation)
[23]. We have also observed differences in the metabolic pro-
file of GBM3 cells, in comparison with GBM1 and GBM2
cells, with a clear upregulation of glycolytic enzyme LDHC1
(Lactate-dehydrogenase-C1) expression and a significant
reduction in the expression of the mitochondrial enzyme
ACSS1 (Acyl-CoA synthetase short-chain family-member1)
(Figure 1(e)). Moreover, OOS induced the expression of sev-
eral antioxidant enzymes in GBM1 and GBM2, but not in
GBM3 (Figure 1(f)). We also checked the status of the detox-
ifying Nrf-2 (Nuclear factor erythroid-2-related factor 2) sys-
tem. Nrf-2 can be modulated in response to redox imbalance
[24] and it induces the expression of several antioxidative
genes like hemoxygenase-1 (HO-1) and NAD(P)H Quinone
Dehydrogenase 1 (NQO-1) [25]. OOS augmented the levels
of Nrf-2 protein in the three cell lines, although the expres-
sion of its targets was induced in GBM1 and GBM2 cells
but not in the GBM3 line, being GBM1 the one that responds
to lower levels of OOS at shorter times (Figure 1(g)). All these
results reinforce the idea that the metabolic and redox pro-
files of GBM3 cells, compared to GBM1 and GBM2 cells,
are quite different and this might be the cause for their lack
of response to OOS. Moreover, the results suggest that the
expression of some of these proteins could be used as bio-
markers of response to OOS.
3.2. The Growth of Some GBMs Is Impaired by Systemic
Administration of OOS. CSCs in GBM have been associated
with tumor initiation and growth. In order to test if the inhi-
bition of self-renewal induced by OOS in vitro has an effect
on tumor growth, we injected the three primary GBM lines
into the flanks of immunodeficient (nude) mice. When
tumors became visible, animals received intragastric admin-
istration of OOS and tumor growth was monitored with a
caliper. The results showed that there was a significant
reduction in tumor growth in GBM1, a small but not sig-
nificant inhibition of GBM2 growth, and no reduction in
GBM3 tumors (Figures 2(a)–2(c)). Histological analysis of
GBM1 tumors showed no changes in the number of mito-
ses or in the number of Activated Caspase 3-positive cells
(Supp. Figure S2), suggesting that OOS does not affect
overall tumor growth or survival, which correlates with the
lack of effect on cell viability (Figure 1(a)). Moreover, we
observed a significan change in GBM1 tumors in the
expression of the marker NESTIN, associated with GBM
CSCs, which was not observed in GBM3 tumors
(Figure 2(d)). This reinforces the idea that OOS reduces the
stem cell properties of certain GBMs, affecting tumor growth.
With the goal of measuring the effect of OOS in an ortho-
topic setting, we performed an intracranial injection of
GBM1 cells in nude mouse brains. We observed that systemic
administration of OOS reduces tumor burden (Figure 3(a)).
To further quantify tumor growth, we dissected the right
hemispheres from the mouse brains and we measured the
expression of β-tubulin, with primers that recognize specifi-
cally the human sequence. We compared it with the expres-
sion of the RNA polymerase subunit-2 (RPII), measured
with primers that equally recognize both human and mouse
sequences. In the dissected brains, we observed a significant
reduction in the human component (Figure 3(b)), confirm-
ing that the effects of OOS are visible in the brain. We also
dissociated the injected hemispheres and we analyzed the
cells using flow cytometry, measuring a strong reduction in
the percentage of CD44+ cells (Figure 3(c)). CD44 is consid-
ered a marker for GBM CSCs [26, 27], reinforcing the idea
that OOS affects GBM1 tumor growth by impairing CSCs.
3.3. OOS Stimulates Changes in the Macrophage Component
of GBM Tumors. Other authors have suggested that OOS
increases the level of inflammatory cytokines [15]. To check
if OOS has an effect on the immune component of GBMs,
we performed a qRT-PCR analysis of a panel of markers of
mouse lymphoid and myeloid cells in the dissected GBM1
and GBM3 tumors. We detected a change in macrophage
polarization markers after OOS treatment, with a significant
decrease in the expression of M2 (immunosuppressive) genes
in GBM1 tumors as well as in GBM3 tumors (Figure 4(a)).
We also detected an increase in some M1 (inflammatory)
genes after OOS treatment, but only in GBM1 tumors
(Figure 4(b)). GBM can contain large amounts of microglia
and tumor-infiltrating macrophages, and their density is pos-
itively correlated with glioma grade, which suggests that they
support tumor progression [28]. In fact, pharmacological
or genetic inhibition of macrophage recruitment and M2
polarization blocks glioma growth [29]. Glioma-associated
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Figure 1: Continued.
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macrophages have been associated with proangiogenic,
proinvasive and immunosuppressive functions, similar to
those of alternatively activated M2 macrophages [30].
In order to decipher if OOS has a direct effect on macro-
phages, we cultured peritoneal macrophages in the presence
and in the absence of the supplement. To induce M1 or M2
polarization, we used LPS (lipopolysaccharide) and IL4
(interleukin 4), respectively. We also incubated the macro-
phages in the presence of glioma-conditioned media (CM)
(from GBM1). It has been shown that glioma cells release
several factors that recruit and promote the growth of macro-
phages [28, 31]. We first determined that the viability of the
macrophages was only slightly affected by the presence of
OOS, although there was a clear stimulation in the presence
of glioma-CM (Figure 5(a)), which was not able to induce
M1 differentiation (data not shown). OOS did not signifi-
cantly change the expression of M1 markers (in the absence
or in the presence of LPS) (Figure 5(b)), although a small
increment was observed in control-treated cells (P = 0 12).
However, OOS clearly inhibited the upregulation of M2
markers induced by IL4 incubation and, to a lesser extent,
by glioma-CM (Figure 5(c)), suggesting that OOS has a direct
effect on these tumor inflammatory cells. Moreover, we
observed that OOS was able to reduce the levels of ROS in
the macrophages, independently of the differentiation stimuli
(Figure 5(d)).
Macrophages that infiltrate glioma tissues are closely
involved in the development of the tumor microenvironment
by inducing angiogenesis, immunosuppression and invasion
[28]. Moreover, it has been suggested that they can promote
directly tumor cell proliferation. In order to analyze if the
changes in macrophage polarization induced by OOS could
affect secondarily glioma cells, we incubated GBM1 cells on
top of macrophages that had been previously polarized by
IL4, in the presence or in the absence of OOS. Results in
Figure 5(e) suggest that there is indeed a protumoral function
of M2 macrophages on glioma cells, as they support GBM1
growth even in the absence of growth factors. More impor-
tantly, pretreatment with OOS severely impaired this growth
induction.
Altogether, these data reinforce the antitumor potential
of OOS, as it could target CSCs and their supportive immu-
nosuppressive microenvironment. However, in the xenograft
setting, this general change in M2 polarization does not seem
to be enough to inhibit tumor growth as OOS had no effect
on GBM3 tumors (Figure 2), even though M2 markers were
diminished (Figure 4(a)).
4. Discussion
In this study, we have evaluated the antitumor action of
OOS in GBM using several human primary cell lines.
OOS was able to reduce the in vivo growth of some of the
GBM lines tested. We did not detect any changes in prolif-
eration or cell death in the most sensitive tumors (GBM1
cells) (Supplementary Figure S1), suggesting that OOS
does not have an effect on the overall tumor cell viability,
as we had observed in the in vitro assays. However, there
was a significant decrease in stem cell markers (NESTIN or
CD44 expression) in response to OOS in vitro and in vivo.
Moreover, the inhibition of the self-renewal capacity of
GBM cells further confirmed that OOS inhibits the stem
cell properties. Therefore, we cannot discard that OOS
could be affecting proliferation or survival in the GBM
CSC population.
Glioma CSCs are enriched in areas of high oxidative
stress [4, 5]. Paradoxically, it has been suggested that low
levels of ROS are required for stem cells to maintain
GBM1 GBM2 GBM3
OOS




















































Figure 1: OOS inhibits the self-renewal capacity of GBM cells. (a) Cell viability of GBM cells in response to OOS (3d), n = 3. (b) Formation of
GBM clonal spheres in the presence of OOS (6d), n = 3. (c, d) Relative expression (qRT-PCR) of CSC-related markers in GBM1 (c) and GBM3
(d) cells treated in the absence or in the presence of OOS (24 h), n = 3. (e) Relative expression (qRT-PCR) of metabolic markers in the three
different GBM lines, n = 3. (f) Induction of the expression of several antioxidant enzymes in the presence of OOS (24 h), n = 3. RPII was used
for normalization in all qRT-PCRs. (g) GBM cells were treated with OOS (1 : 100 or 1 : 50) for 2 or 24 h and expression of Nrf-2, NQO-1, and
HO-1 was measured by WB. Nontreated spheres were used as a control and the expression of GAPDH as a loading control. The blots in the
image were cropped from the same gel (full-length blots are shown in Supp. Figure S1). ∗P ≤ 0 05; ∗∗P ≤ 0 01; ∗∗∗P ≤ 0 001.
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quiescence and self-renewal, both in normal tissues and
tumors [32]. In gliomas, CSCs appear to generate less ROS
and have a higher ROS-scavenging capacity than more differ-
entiated tumor cells [33]. In fact, an increase in mitochon-
drial ROS has also been linked to the loss of stem cell
markers [34]. In contrast, our results indicate that the main
effect of the antioxidant OOS is a decrease in the stemness
properties of GBM. This observation agrees with recent
results obtained with several ROS-scavenging compounds
[7, 8]. Based on these data, it could be hypothesized that cer-
tain levels of ROS may be necessary to maintain CSCs in
GBM cells, although too much oxidative stress could be also



































































































Figure 2: OOS inhibits GBM growth. GBM1-3 cells were injected subcutaneously into the flanks of nude mice; when tumors became visible,
animals started receiving daily oral doses of OOS (100 μl/day, 5 days/week) or water (control). Relative tumor growth at different time points
(a) or the time of sacrifice (b) is represented, n = 8. (c) Representative pictures of the tumors are shown. (d)NESTIN expression (qRT-PCR) in
flank tumors after OOS treatment, n = 4. RPII was used for normalization in all qRT-PCRs. ∗P ≤ 0 05. Scale bar = 1 cm.
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detrimental. Antioxidants could, therefore, deregulate this
oxidative stress equilibrium, affecting stem cell properties
and tumor growth.
Not all GBM CSCs seem to be sensitive to OOS. The sup-
plement did not inhibit the clonal growth of GBM3 cells and
it did not slow down the growth of GBM3 tumors, suggesting
that CSCs from GBM3 are less sensitive to OOS than those
from GBM1 or GBM2. It is important to remark that OOS
was able to induce the expression of several antioxidant
enzymes, but only in GBM1 and GBM2 cells. Moreover, the
expression of some metabolic enzymes was very different in
GBM3 cells compared to the other two lines, suggesting that
the redox and the metabolic status of the glioma cells may
determine their response to OOS. It would be interesting to
test, in a larger cohort study, if the expression of some of
these enzymes could be used as a predictive marker for the
efficacy OOS or other antioxidant compounds.
Apart from the direct effect of OOS in GBM tumor cells,
our data reflect that there was a change in the inflammatory
component of the tumors, with a weaker expression of M2
macrophage markers in tumors treated with OOS. Glioma
cells in general, and CSCs in particular, release several factors
that recruit and promote the growth of macrophages [28, 31].
Therefore, changes in the properties of CSCs induced by
OOS could be affecting the surrounding myeloid cells.
Although we cannot discard such indirect effect, our results
in vitro clearly indicate that OOS affects macrophage polari-
zation in a direct way, reducing the expression of M2markers
in response to a classical inducer like IL4 but also in response
to glioma-CM. We also confirmed that OOS reduces the
levels of ROS in the macrophages in all the conditions tested.
Although ROS production is usually associated with the
activation and function of M1 macrophages [28], it has
been recently shown that ROS are important in M2 but not
in M1 macrophage differentiation. Thus, antioxidants like
BHA (butylated hydroxy-anisole) [35], dihydroxycoumarins
[36], or caffeic acid [37] inhibit M2 but not M1 polarization
and prevent tumor growth and metastasis formation. Fur-
thermore, chlorogenic acid, a product with antibacterial
and antioxidant properties, inhibits the growth of GBM
through the repolarization of macrophage from M2 to M1
phenotype [38]. Therefore, OOS could exert their antitu-
morigenic action, at least in part, through the inhibition of
M2 differentiation. Other authors have observed an increase
in proinflammatory cytokines like IL6 in mouse models of
acute leukemia treated with OOS [15], suggesting that the
macrophage-polarization effect of OOS could be extended
to other cancers. In our hands, however, OOS does not
induce a significant increase in the expression of M1 markers
in LPS-treated macrophages, although IL18 (but not NOS2)
is overexpressed in GBM1 tumors treated with OOS. IL18
is another cytokine secreted by M1 macrophages that partic-
ipates in the activation of T cell-mediated inflammatory
responses [39]. Interestingly, in GBM3 tumors, M2 markers
are also inhibited whereas IL8 expression is not induced in
response to OOS. This could participate in the lack of
response of these cells to the dietary supplement. Moreover,
these results suggest that other components of the glioma
(including the tumor cells) might modulate the response of
macrophages to OOS, making some tumors more susceptible
to these changes than others.
It is important to remark that, in our hands, treatment
with OOS does not have any apparent toxic effect since no
differences were observed in animal weight or behavior in




















































Figure 3: OOS inhibits intracranial tumor growth. GBM1 cells were
injected into the brains of nude mice. The animals were treated
orally with daily doses of OOS (200 μl, 5 days/week) or water
(control). (a) Animal survival was evaluated using a Kaplan-Meier
survival curve and the differences in survival times were analyzed
with a log-rank test, n = 7. (b) qRT-PCR analysis of human β-
tubulin (human TUB) related to RPII (human and mouse) levels
in the dissected brains. Each bar represents one tumor. (c)
Percentage of CD44+ cells in dissociated brain tumors analyzed by
flow cytometry, n = 3. ∗P ≤ 0 05.
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antioxidant supplements during treatment because it has
been reported that they may have detrimental effects or even
undesirable interactions with certain therapies. However,
several articles have concluded that antioxidant supplements
do not undermine the effectiveness of cytotoxic therapies
[10]. Therefore, it would be interesting to find out if there is
a synergy between OOS and the conventional chemotherapy
(TMZ), as it has been shown in other types of cancer [15, 40].
The fact that OOS has been marketed for years without
any report of adverse effects would help in verifying this
synergism in the clinic. Moreover, it would be interesting to
test whether OOS could have a similar beneficial effect in
combination with radiotherapy or even for the novel immu-
notherapies that are currently in early clinical phases.
5. Conclusions
(i) The presence of Ocoxin® oral solution (OOS)
inhibits the self-renewal capacity of a percentage of
primary glioblastoma (GBM) cell lines
(ii) Systemic treatment with OOS reduces tumor burden






















































































































































































Figure 4: OOS affects macrophage polarization in vivo. GBM1 and GBM3 flank tumors were dissociated and the expression of different M2
(a) or M1 (b) markers was determined by qRT-PCR (n = 6). Mouse Actin was used for normalization. ∗P ≤ 0 05.
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(e)
Figure 5: OOS affects macrophage polarization in vitro. (a) Cell viability was measured in the presence of the different stimuli. (b, c)
Macrophage pellets were processed for qRT-PCR analysis of M1 (b) and M2 (c) genes. Mouse Actin was used for normalization, n = 3. (d)
Analysis of ROS levels with DHE reagent in macrophages treated with the different stimuli, with or without OOS, n = 5. (e) Peritoneal
macrophages were incubated in the presence of IL4 and OOS. After washing the macrophages, GBM1 cells were dissociated and plated on
top of the macrophages or in control plates (with or without growth factors). Three days later, luciferase activity was measured in an IVIS
equipment, n = 3. ∗P ≤ 0 05; ∗∗P ≤ 0 01; ∗∗∗P ≤ 0 001; ∗∗∗∗P ≤ 0 0001.
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(iii) OOS inhibits M2 protumoral polarization of macro-
phages in vitro
(iv) Systemic treatment with OOS inhibits the M2 protu-
moral polarization of glioma-associated macrophages
(v) OOS is a feasible candidate to be used in combina-
tion therapies during the treatment of GBM patients
Data Availability
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to support the findings of this study are included within the
article and within the supplementary information files.
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Supplementary Figure S1: full-length blots of Figure 1(g).
GBM cells were treated with OOS (1 : 100 or 1 : 50) for 2 or
24 h and expression of Nrf-2 and NQO-1, and HO-1 was
measured by WB. Nontreated spheres were used as a control
and the expression of GAPDH as a loading control. Supple-
mentary Figure S2: OOS does not induce overall changes in
proliferation or cell death in GBM1 tumors. Paraffin sections
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